Sickening

1. America's Healthcare Paradox: High Cost, Poor Health.

Not only is our health worse, but the pace at which we are falling behind is accelerating.

Unparalleled spending. The United States spends an exorbitant amount on healthcare, approximately 17.7% of its GDP annually, which is 7% more than the average of other wealthy nations. This translates to an excess of $1.5 trillion spent each year, or an unlegislated tax of $4,500 per person. Despite this massive investment, Americans are demonstrably less healthy than citizens of other affluent countries.

Declining health metrics. The health of Americans is not only worse but deteriorating rapidly. For instance, the rate of preventable deaths is 50% higher than the average of nine other wealthy countries. Since 2000, healthy life expectancy in the U.S. has plummeted from 38th to 68th globally by 2019, now trailing nations like China, Cuba, and Jamaica.

Beyond disparities. While racial and economic disparities contribute to poor health outcomes, even privileged Americans with high incomes, education, and insurance suffer worse health compared to their counterparts in other wealthy nations. This suggests a systemic issue beyond access, where the focus on "breakthrough medical innovation" overshadows alarms about declining public health.

2. Big Pharma's Profit-First Imperative Drives Systemic Dysfunction.

Big Pharma does not set out to purposely harm Americans’ health, but its primary job has become the exploitation of each situation as a unique opportunity to maximize profits, regardless of the overall impact on society.

Profit over patients. The pharmaceutical industry's primary goal is to maximize profits, not necessarily to improve Americans' health. This objective masterfully controls the medical research agenda, from study design and analysis to the dissemination of results, ensuring that information is curated to boost drug sales. This profit-driven approach has led to a "tail wags dog" situation in American healthcare.

COVID-19 vaccine example. The pandemic starkly illustrated this dynamic. While the U.S. government invested heavily in vaccine development (Operation Warp Speed), foundational research was largely publicly funded by NIH scientists. Drug manufacturers like Moderna and Pfizer then leveraged this public investment and the global crisis to secure "ransomlike" pricing and generate billions in profits, creating new billionaires, while neglecting global vaccine equity.

Consequences of unchecked greed. This relentless pursuit of profit, often at the public's expense, has tangible and tragic consequences. The gross overselling of prescription opioids, for example, contributed to tens of thousands of American deaths annually. This pattern of prioritizing financial gain, even when it involves misleading the public or ignoring global health needs, makes understanding "business as usual" in the pharmaceutical industry jarring.

3. The "Knowledge Problem": Commercial Control Distorts Medical Science.

The pharmaceutical companies now control most of the medical research agenda, and their primary goal is not to improve Americans’ health but to maximize their own profits, which they do masterfully.

Erosion of independence. Over the past four decades, public funding for clinical research and federal support for university-based medical research have declined, allowing drug companies to fill the void. This shift has led to increased commercial influence over the information doctors rely on for optimal patient treatment, fundamentally altering the pursuit of medical knowledge.

Ghostwriting and data ownership. Academic researchers, once independent guardians of scientific integrity, now often participate in commercially sponsored clinical trials where drug companies own the data and even ghostwrite manuscripts. A survey revealed that 50% of research contracts between drug companies and academic institutions allowed commercial sponsors to write up results, relegating named authors to merely "suggesting revisions."

"Marketing-based medicine." This commercialization means that the purpose of most new medical knowledge is to support the use of new drugs and biomedical interventions, rather than to genuinely advance public health. Pfizer's internal documents explicitly state that the purpose of their clinical trials is to create data "to support, directly or indirectly, marketing of our product," transforming evidence-based medicine into marketing-based medicine.

4. Trusted Medical Sources Compromised by Lack of Data Transparency.

One of the best-kept secrets in all of health care — understood by few doctors — is that the peer reviewers, medical journal editors, and guideline writers, who are assumed to be performing due diligence to ensure the accuracy and completeness of the data reported from company-sponsored studies, do not have access to the real data from these trials.

Unverified "scientific evidence." Doctors are taught to rely on peer-reviewed medical journals, clinical practice guidelines, and respected authorities for scientific evidence. However, these trusted sources often publish unverified data summaries prepared largely by or for sponsoring drug companies. Without access to raw, patient-level data, peer reviewers and editors cannot independently confirm the accuracy or completeness of reported findings.

Journal complicity. Medical journals, especially the most prestigious, have a significant financial incentive to publish commercially sponsored studies. Reprint sales of articles, often purchased by drug companies for marketing, can account for a substantial portion of a journal's income (e.g., 41% of The Lancet's total income in 2005). This creates a conflict of interest, prioritizing profit over rigorous scientific vetting.

The "iceberg" of data. Only a small fraction of clinical trial data is visible in published articles, like the tip of an iceberg. The vast majority remains "below the waterline," inaccessible to independent scrutiny. This lack of transparency allows drug companies to selectively present favorable results while obscuring less desirable outcomes, making it impossible for doctors to distinguish accurate from incomplete information.

5. Marketing Tactics "Phish" Doctors, Leading to Suboptimal Patient Care.

The more effective the drug company’s marketing, the more difficult will be the doctor’s decision not to accept the supposedly authoritative scientific evidence.

Exploiting doctor vulnerabilities. Drug companies skillfully employ behavioral economics tactics to "phish" doctors, exploiting their natural tendencies. These include a sense of reciprocal obligation from gifts and meals, a desire to be polite, reluctance to contradict authority, and a need for internal consistency in their practice. Even small gifts can significantly influence prescribing patterns towards more expensive brand-name drugs.

Key messages as propaganda. Marketing departments craft "key messages" that are road-tested to effectively persuade doctors, often exaggerating benefits and minimizing risks. These messages are integrated into branding strategies and disseminated through various channels, including medical journals and educational events. A Pfizer internal document explicitly showed how marketing messages were designed to "align" with, rather than reflect, scientific findings.

Branding over science. The success of drugs like Nexium and OxyContin demonstrates the power of branding to create perceived superiority, even when scientific evidence is lacking or contradictory. AstraZeneca's Nexium, for example, became a blockbuster by creating the illusion of innovation through dosage manipulation and selective publication of studies, despite offering no real advantage over its cheaper predecessor, Prilosec. Purdue Pharma's OxyContin was marketed as less addictive and long-acting, directly contradicting its own studies and contributing to the opioid crisis.

6. Unregulated Drug Pricing and Information Asymmetry Create Market Failure.

Our uniquely market-based approach to the pricing and distribution of prescription drugs is uniquely inefficient.

Monopoly pricing. The U.S. is the only wealthy country without a national mechanism to regulate prescription drug prices. Manufacturers are granted market exclusivity for new drugs, allowing them to set prices arbitrarily. This results in Americans paying nearly twice as much per person annually for prescription medications compared to other wealthy nations, leading to an estimated $170 billion in excess costs each year.

Information asymmetry. The pharmaceutical market fundamentally differs from Adam Smith's classical model. Consumers (patients) cannot choose drugs, doctors are often price-insensitive, and insurance shields most consumers from the full cost. Crucially, drug companies possess far more information about their products' true value than doctors or patients, enabling them to manipulate beliefs and sales.

Prohibition of cost-effectiveness. U.S. government agencies, including the FDA, are explicitly prohibited from evaluating the comparative clinical benefit and cost-effectiveness of new drugs. This legislative barrier, reinforced by lobbying efforts (e.g., Pharma's $150 million support for Obamacare, which banned cost-effectiveness studies), prevents rational decision-making and perpetuates market inefficiencies.

7. The Research Agenda is Skewed Towards Profit, Not Public Health Needs.

Left to its own devices, the market has no incentive (actually, it has a negative incentive) to fund research to determine the interventions with the greatest health benefit.

Misaligned priorities. The vast majority (96%) of U.S. biomedical research funding is directed towards developing and testing new drugs and medical devices. This focus, driven by market incentives, creates a body of scientific evidence that prioritizes financial return over addressing Americans' actual health needs. Consequently, doctors and patients are led to believe that technological innovation is the primary path to good health, despite medical care accounting for only about 20% of longevity.

Ignoring upstream solutions. The market has little incentive to fund research into less profitable "upstream approaches" like lifestyle modifications, even when they offer greater health benefits. For example, the Diabetes Prevention Program showed lifestyle changes were significantly more effective than drug therapy in preventing type 2 diabetes. Yet, expensive diabetes drugs like Trulicity, with minimal cardiovascular benefits at enormous cost, receive extensive research and marketing.

Excessive returns on investment. The synergy of unregulated pricing, control over research, and lack of government oversight has made Big Pharma an investor's "golden goose," consistently yielding profit margins at least twice as high as other major corporations. This overcapitalization fuels a cycle of product development and marketing that further shapes beliefs, increases sales of overpriced products, and funds lobbying efforts to maintain the status quo.

8. Obamacare Expanded Coverage But Failed to Address Core Cost and Quality Issues.

But in the legislative process that produced Obamacare, broader reforms — including government-sponsored cost-effectiveness research and a public option to compete on the exchanges with private insurance plans — met with insurmountable resistance.

Limited reform scope. Obamacare successfully expanded health insurance coverage to millions of previously uninsured Americans, a significant accomplishment. However, it largely avoided challenging the powerful vested interests in the healthcare industry. Key cost-containing features, such as government-sponsored cost-effectiveness research and a robust public option, were stripped from the legislation due to intense lobbying.

Appeasing vested interests. The pharmaceutical industry, insurance companies, and hospitals supported Obamacare's coverage expansion because it created more customers, guaranteeing increased revenue. This "win-win" approach meant that while more Americans gained insurance, the underlying drivers of high costs and compromised quality remained unaddressed, leading to increased profits for these industries.

Unmet public demand. Despite widespread public dissatisfaction with healthcare costs (79% of Americans) and strong support for measures like a public option (68%), government policy has consistently failed to reflect these preferences. This highlights the disproportionate influence of "economic elites and organized groups representing business interests" over the will of ordinary citizens in shaping healthcare legislation.

9. Meaningful Reform Requires Reclaiming Scientific Integrity and Market Fairness.

The health-care reform we need now — to improve Americans’ health, reduce health-care costs, and move toward universal coverage — must break out of the politically safe confines of “win-win,” in which coverage is expanded only by increasing the profits of the vested interests.

Beyond "win-win" reform. True healthcare reform must move beyond expanding coverage while simultaneously enriching vested interests. It requires "zero-sum reform," where private profits are no longer maximized at the public's expense. This means rebalancing the market for prescription drugs, forcing manufacturers to compete on true effectiveness, safety, and value, as determined by independent analyses.

Five pillars of integrity. To fix the "knowledge problem," five critical measures are needed:

• Rebalance research agenda: Shift focus from profitable innovation to actual health needs.
• Design for optimal care: Require new products to be tested against the best available therapies, including lifestyle interventions.
• Data transparency: Mandate full access to clinical trial data for all authors, peer reviewers, and editors before publication.
• Informative DTC ads: Ensure direct-to-consumer advertising provides accurate, balanced information on benefits, risks, and costs.
• Government oversight: Implement robust regulation to ensure competitive markets, enforce contracts, and hold individuals accountable for illegal marketing.

Health Technology Assessment (HTA). Re-establishing a federally funded HTA agency, similar to the UK's NICE, is crucial. This agency would provide unbiased evaluations of the clinical and economic value of new therapies, guiding prescribing decisions and informing national drug coverage and pricing policies. This would counter the current system where U.S. federal agencies are prohibited from considering drug prices in coverage decisions.

10. A Unified Coalition of Stakeholders is Essential to Challenge Corporate Power.

Success will require that all stakeholders — including doctors and other health-care providers, large and small non-health-care-related businesses, unions, government entities at all levels that pay for health care, and consumers — act in alliance to overcome the drug companies’ control of the medical knowledge they now produce, manipulate, and distribute.

Empowering health professionals. Doctors, nurses, and other healthcare professionals are natural leaders for reform. They must recognize how their beliefs are manipulated by industry-distorted scientific evidence. By insisting on data transparency, commercially uninfluenced guidelines, and independent HTA, they can reclaim their role as learned intermediaries, prioritizing patient health over corporate profits.

Payers demanding value. Employers, unions, and government entities that fund healthcare must demand fair value for their spending. This means advocating for independent HTA, ensuring oversight organizations are free of commercial sponsorship, and pressuring Congress to control drug prices and support public health research. Their collective purchasing power is a formidable, yet underutilized, force.

Informed consumer advocacy. All citizens, as healthcare consumers, must understand that heavily advertised drugs are pushed for financial gain, not necessarily for superior health value. They must advocate for a medical research agenda that prioritizes overall health, including lifestyle factors, and demand that elected representatives support reforms that rebalance medical spending with investments in social determinants of health. This unified front is the only way to overcome the immense political and economic power of the healthcare industry.